Reminyl (Galantamine Hydrobromide) - Summary

REMINYL SUMMARY

REMINYL® (galantamine hydrobromide) is a reversible, competitive acetylcholinesterase inhibitor.

REMINYL® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

REMINYL NEWS HIGHLIGHTS

Media Articles Related to Reminyl (Galantamine)

Advances In Conceptualizing Disease Progression In Alzheimer's Disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2008.08.26]

Alzheimer's Disease: Home Safety Information
Source: MedicineNet Advance Medical Directives Specialty [2008.08.26]

Alzheimer's Disease Patient Caregiver Guide
Source: MedicineNet Dehydration Specialty [2008.08.26]

Alzheimer's Disease: Compounds Have Potential For Diagnosis, Treatment
Source: Genetics News From Medical News Today [2008.08.23]

Initiatives Seek To Reduce Salt Intake Among Blacks, Offer Health Benefits Assistance To Hispanics, Examine Caring For People With Alzheimer's Disease
Source: Hypertension News From Medical News Today [2008.08.18]

more>>

Published Studies Related to Reminyl (Galantamine)

Analyses of mortality risk in patients with dementia treated with galantamine. [2008.06.01]

Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). [2008.02.28]

Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study. [2008.02]

Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. [2008.02]

Galantamine for the treatment of cognitive impairments in people with schizophrenia. [2008.01]

more>>

Clinical Trials Related to Reminyl (Galantamine)

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]

A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL®) in Patients With Alzheimer's Disease [Completed]

A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]

A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease [Completed]

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia [Completed]

more>>